原始出處紀錄
Lantheus 簽署最終協議,將其 CDMO 業務及紐澤西州斯普林菲爾德廠房出售予 PharmaLogic。雙方同時同意簽署長期供應協議,由 PharmaLogic 的 Agilera 為 Lantheus 製造 lutetium Lu 177 dotatate。
8-K false 0001521036 0001521036 2026-11-08 2026-11-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2026 LANTHEUS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36569 35-2318913 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 201 Burlington Road South Building Bedford , Massachusetts 01730 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (978) 671-8001 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropri